FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1933431079> ?p ?o ?g. }

• W1933431079 endingPage "1544" @default.
• W1933431079 startingPage "1531" @default.
• W1933431079 abstract "Abstract Purpose: Flightless I (FLII), member of the gelsolin superfamily of actin-remodeling proteins, functions as a transcriptional coregulator. We aim to evaluate a tumor-suppressive function of FLII in regulating androgen receptor (AR) in prostate cancer progression. Experimental Design: We examined FLII protein and mRNA expression in clinical prostate cancer specimens by immunohistochemistry. Kaplan–Meier analysis was conducted to evaluate the difference in disease–overall survival associated with the expression levels of FLII and AR. Prostate cancer cells stably expressing FLII or shRNA knockdown were used for functional analyses. Immunoprecipitation, Luciferase reporter, and immunofluorescence staining assays were performed to examine the functional interaction between FLII and AR. Results: Our analysis of the expression levels of FLII in a clinical gene expression array dataset showed that the expression of FLII was positively correlated with the overall survival of prostate cancer patients exhibiting high levels of AR expression. Examination of protein and mRNA levels of FLII showed a significant decrease of FLII expression in human prostate cancers. AR and FLII formed a complex in a ligand-dependent manner through the ligand-binding domain (LBD) of AR. Subsequently, we observed a competitive binding to AR between FLII and the ligand. FLII inhibited AR transactivation and decreased AR nuclear localization. Furthermore, FLII contributed to castration-sensitive and castration-resistant prostate cancer cell growth through AR-dependent signaling, and reintroduction of FLII in prostate cancer cells sensitized the cells to bicalutamide and enzalutamide treatment. Conclusions: FLII plays a tumor-suppressive role and serves as a crucial determinant of resistance of prostate cancer to endocrine therapies. Clin Cancer Res; 22(6); 1531–44. ©2015 AACR." @default.
• W1933431079 created "2016-06-24" @default.
• W1933431079 creator A5008032475 @default.
• W1933431079 creator A5022310004 @default.
• W1933431079 creator A5023282904 @default.
• W1933431079 creator A5045127642 @default.
• W1933431079 creator A5052134746 @default.
• W1933431079 creator A5063466159 @default.
• W1933431079 creator A5065238326 @default.
• W1933431079 creator A5065564993 @default.
• W1933431079 creator A5072201399 @default.
• W1933431079 creator A5079886307 @default.
• W1933431079 creator A5084188467 @default.
• W1933431079 creator A5085142676 @default.
• W1933431079 creator A5086664647 @default.
• W1933431079 date "2015-03-15" @default.
• W1933431079 modified "2023-10-16" @default.
• W1933431079 title "Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling" @default.
• W1933431079 cites W1458426854 @default.
• W1933431079 cites W1506633809 @default.
• W1933431079 cites W1541668489 @default.
• W1933431079 cites W1745328274 @default.
• W1933431079 cites W1755643198 @default.
• W1933431079 cites W1971366553 @default.
• W1933431079 cites W1982232522 @default.
• W1933431079 cites W1996739656 @default.
• W1933431079 cites W2002345676 @default.
• W1933431079 cites W2002576665 @default.
• W1933431079 cites W2010246016 @default.
• W1933431079 cites W2020021476 @default.
• W1933431079 cites W2020646112 @default.
• W1933431079 cites W2024648144 @default.
• W1933431079 cites W2036976345 @default.
• W1933431079 cites W2042779449 @default.
• W1933431079 cites W2043772860 @default.
• W1933431079 cites W2047588393 @default.
• W1933431079 cites W2055356264 @default.
• W1933431079 cites W2064293531 @default.
• W1933431079 cites W2079039801 @default.
• W1933431079 cites W2083954183 @default.
• W1933431079 cites W2085370227 @default.
• W1933431079 cites W2091869504 @default.
• W1933431079 cites W2092646174 @default.
• W1933431079 cites W2102312420 @default.
• W1933431079 cites W2106110723 @default.
• W1933431079 cites W2107633226 @default.
• W1933431079 cites W2107958146 @default.
• W1933431079 cites W2112202844 @default.
• W1933431079 cites W2118650392 @default.
• W1933431079 cites W2128410150 @default.
• W1933431079 cites W2129456080 @default.
• W1933431079 cites W2130277194 @default.
• W1933431079 cites W2131077462 @default.
• W1933431079 cites W2133855305 @default.
• W1933431079 cites W2139242035 @default.
• W1933431079 cites W2146314117 @default.
• W1933431079 cites W2148207479 @default.
• W1933431079 cites W2154968444 @default.
• W1933431079 cites W2158107674 @default.
• W1933431079 cites W2160314486 @default.
• W1933431079 cites W2165854061 @default.
• W1933431079 cites W2167768067 @default.
• W1933431079 cites W2171450779 @default.
• W1933431079 cites W2418869537 @default.
• W1933431079 cites W4232922151 @default.
• W1933431079 cites W4246180691 @default.
• W1933431079 doi "https://doi.org/10.1158/1078-0432.ccr-15-1632" @default.
• W1933431079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26527749" @default.
• W1933431079 hasPublicationYear "2015" @default.
• W1933431079 type Work @default.
• W1933431079 sameAs 1933431079 @default.
• W1933431079 citedByCount "22" @default.
• W1933431079 countsByYear W19334310792015 @default.
• W1933431079 countsByYear W19334310792016 @default.
• W1933431079 countsByYear W19334310792017 @default.
• W1933431079 countsByYear W19334310792018 @default.
• W1933431079 countsByYear W19334310792019 @default.
• W1933431079 countsByYear W19334310792020 @default.
• W1933431079 countsByYear W19334310792021 @default.
• W1933431079 countsByYear W19334310792022 @default.
• W1933431079 countsByYear W19334310792023 @default.
• W1933431079 crossrefType "journal-article" @default.
• W1933431079 hasAuthorship W1933431079A5008032475 @default.
• W1933431079 hasAuthorship W1933431079A5022310004 @default.
• W1933431079 hasAuthorship W1933431079A5023282904 @default.
• W1933431079 hasAuthorship W1933431079A5045127642 @default.
• W1933431079 hasAuthorship W1933431079A5052134746 @default.
• W1933431079 hasAuthorship W1933431079A5063466159 @default.
• W1933431079 hasAuthorship W1933431079A5065238326 @default.
• W1933431079 hasAuthorship W1933431079A5065564993 @default.
• W1933431079 hasAuthorship W1933431079A5072201399 @default.
• W1933431079 hasAuthorship W1933431079A5079886307 @default.
• W1933431079 hasAuthorship W1933431079A5084188467 @default.
• W1933431079 hasAuthorship W1933431079A5085142676 @default.
• W1933431079 hasAuthorship W1933431079A5086664647 @default.
• W1933431079 hasBestOaLocation W19334310792 @default.
• W1933431079 hasConcept C104317684 @default.
• W1933431079 hasConcept C121608353 @default.

• next